- Conditions
- OSA
- Interventions
- AD109, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 59 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–128
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease
- Interventions
- Strattera, Exelon, Placebo
- Drug · Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- OSA
- Interventions
- AD109
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Anniston, Alabama • Jacksonville, Florida • Monroe, North Carolina + 1 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder, ADHD
- Interventions
- ABT-894, atomoxetine, placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 22
- States / cities
- San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
- Conditions
- Parkinson's Disease, Cognitive Impairment
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Menopause, Cognitive Disturbances
- Interventions
- atomoxetine, placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Atomoxetine, Buspirone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Diego, California • Orlando, Florida + 5 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
- Interventions
- Atomoxetine hydrochloride, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 20
- States / cities
- Wildomar, California • Bradenton, Florida • Gainesville, Florida + 17 more